Across TCGA pan-cancer cohorts, RPL12 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated RPL12 data layer compared with 31 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher RPL12 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated RPL12 expression acts as an unfavorable survival marker, although some lineages such as HNSC and LSCC show a favorable association.

CCRCC, HNSC, and GBM are the cancer types where RPL12 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	III,IV	0.505	0.851	.001	46	view →
HNSC	OS	Tertile	IV	0.928	0.578	.003	19	view →
GBM	DFS	Median	All	0.282	0.459	.014	8	view →
LSCC	DFS	Median	II,III,IV	1.000	0.849	.011	4	view →
LUAD	DFS	Tertile	All	0.993	0.854	.036	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: RPL12 tumor-vs-normal RNA expression · all RPL12 data types